JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

JNJ

192.08

-0.38%↓

ABT

126.36

-1.14%↓

MDT

94.19

-1.71%↓

VEEV

291.41

+0.69%↑

A

147.65

+1.19%↑

Search

Alkermes PLC

Open

BrancheGesundheitswesen

29.99 -3.54

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

29.88

Max

31.13

Schlüsselkennzahlen

By Trading Economics

Einkommen

65M

87M

Verkäufe

84M

391M

KGV

Branchendurchschnitt

14.613

37.461

Gewinnspanne

22.295

Angestellte

1,800

EBITDA

99M

113M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+29.09% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

28. Okt. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

802M

5.1B

Vorheriger Eröffnungskurs

33.53

Vorheriger Schlusskurs

29.99

Nachrichtenstimmung

By Acuity

50%

50%

168 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Weak Bullish Evidence

Alkermes PLC Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

22. Okt. 2025, 22:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project -- Update

22. Okt. 2025, 22:13 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Signs Up Williams as Investor in Louisiana LNG Project

22. Okt. 2025, 21:20 UTC

Ergebnisse

Correction to IBM 3Q Sales Jump Article

22. Okt. 2025, 20:57 UTC

Ergebnisse

SAP Posts Higher 3Q Revenue, Operating Profit

22. Okt. 2025, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

22. Okt. 2025, 23:46 UTC

Market Talk

Nikkei May Decline Amid U.S.-China Trade Tensions -- Market Talk

22. Okt. 2025, 23:41 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:38 UTC

Market Talk

Gold Extends Pullback on Likely Profit-Taking -- Market Talk

22. Okt. 2025, 23:15 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 4th Update

22. Okt. 2025, 22:28 UTC

Market Talk

Alcoa Cautions About Spending More on U.S. Smelters -- Market Talk

22. Okt. 2025, 22:02 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 3rd Update

22. Okt. 2025, 21:59 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Entered Into 1.5 Mtpa LNG Offtake Obligation >WMB

22. Okt. 2025, 21:58 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 10% Interest in Louisiana LNG LLC >WMB

22. Okt. 2025, 21:57 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos. to Buy 80% Ownership In, Become Operator of Driftwood Pipeline >WMB

22. Okt. 2025, 21:56 UTC

Akquisitionen, Fusionen, Übernahmen

Williams Cos.: Strategic Partnership Entered With Woodside Energy to Invest in Louisiana LNG Project >WMB

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Assume LNG Offtake Obligations for 10% of Produced Volumes

22. Okt. 2025, 21:47 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 21:47 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside: Williams to Contribute Its Share of Capex for LNG Facility, Pipeline

22. Okt. 2025, 21:46 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy Says Williams Deals Worth US$378 Million Including Capital Reimbursement

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 80% Interest in Driftwood Pipeline Co. to Williams

22. Okt. 2025, 21:45 UTC

Akquisitionen, Fusionen, Übernahmen

Woodside Energy to Sell 10% Interest in Louisiana LNG Holding Co. to Williams

22. Okt. 2025, 21:28 UTC

Market Talk
Ergebnisse

Correction to Alcoa Tariff Market Talk

22. Okt. 2025, 21:25 UTC

Ergebnisse

Wall Street Wonders if Grail's Cancer Test Results Are a True Positive -- Barrons.com

22. Okt. 2025, 21:17 UTC

Ergebnisse

Tesla Profit Plunges Despite Third-Quarter Rush to Buy EVs -- 2nd Update

22. Okt. 2025, 21:09 UTC

Market Talk
Ergebnisse

Alcoa Says Delivery Fee Covering Tariff Costs -- Market Talk

22. Okt. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

22. Okt. 2025, 20:59 UTC

Ergebnisse

SAP Stock Drops After Earnings. Cloud Revenue Fell Short. -- Barrons.com

22. Okt. 2025, 20:51 UTC

Ergebnisse

SAP Reports Mixed Earnings. The Stock is Down. -- Barrons.com

22. Okt. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

22. Okt. 2025, 20:44 UTC

Ergebnisse

Kaiser Aluminum: For the Full Yr 2025, Now Expects Conversion Rev to Be Flat to Up 5% Yr-Over-Yr and Raises Adjusted EBITDA Outlook to Improve 20% to 25% Yr-Over-Yr >KALU

Peer-Vergleich

Kursveränderung

Alkermes PLC Prognose

Kursziel

By TipRanks

29.09% Vorteil

12-Monats-Prognose

Durchschnitt 40.6 USD  29.09%

Hoch 47 USD

Tief 33 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Alkermes PLC – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

7

Buy

4

Halten

0

Sell

Technischer Score

By Trading Central

27.95 / 30.91Unterstützung & Widerstand

Kurzfristig

Weak Bullish Evidence

Mittelfristig

Strong Bearish Evidence

Langfristig

Strong Bullish Evidence

Stimmung

By Acuity

168 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Alkermes PLC

Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.
help-icon Live chat